<> /* Style Definitions */ span.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_a
Otsuka Pharmaceutical's anti-APRIL monoclonal antibody VIS649 applied for clinical application in China
Time of Update: 2022-04-30
On March 8, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that Otsuka Pharmaceutical applied for the clinical trial application of VIS649 and was accepted .
[Cell Sub-issue] Fine-tune antibodies to achieve the best anti-infection effect!
Time of Update: 2022-04-30
The process of selecting the best antibodies occurs in the germinal center, and for vaccines to be more effective and durable, scientists need to better understand this important location and the process of how they evolved .
Female patients with anemia and positive anti-double-stranded DNA antibodies, what is the drug of choice for treatment?
Time of Update: 2022-04-29
Link to the previous article: 53-year-old female rheumatoid arthritis patient, which symptom does not appear?
The team of Professor Gao Feng and Professor Xianghui Yu isolated anti-HIV-1 broad-spectrum
Time of Update: 2022-04-26
The research team of Professor Gao Feng and Professor Yu Xianghui from the School of Life Sciences of Jilin University took the rhesus monkey animal model with the longest reported infection
ARD: Anti-RNP antibodies in systemic lupus erythematosus are associated with an interferon gene signature independent of reduced complement levels
Time of Update: 2022-04-18
To elucidate the interrelationship of specific antinuclear antibodies (ANA) , complement and interferon gene signature (IGS) in the pathogenesis of systemic lupus erythematosus (SLE) .
"Science" publishes a Chinese team paper, providing new ideas for the design and development of broad-spectrum anti-COVID-19 antibodies
Time of Update: 2022-03-08
of the Omicron spike trimer with ACE2 and an anti-Omicron antibody" . This study analyzed the high-resolution cryo-electron microscopy structure of the Omicron spike protein binding
The Shanghai Public Health Clinical Center initiated the study of anti-PD-L1 antibody ASC22
Time of Update: 2022-03-07
This study (Clinical Trials Registry Number: NCT05129189) was designed to evaluate the effect of ASC22 (envolimumab) in combination with chidamide in HIV-infected individuals on the viral reservoir of infected latent cells .
Yiming Biotech's anti-LILRB4 antibody IO-202 received FDA Fast Track designation
Time of Update: 2022-03-05
According to public information, IO-202 is a potential "first-in-class" myeloid immune checkpoint inhibitor targeting LILRB4, which has previously been granted orphan drug designation by the FDA for the treatment of AML .
Nature Med: Combination of GD2 and CD47 antibody drug shows broad-spectrum anti-cancer potential
Time of Update: 2022-02-18
Majzner, Stanford University Nature Medicine Nature Medicine Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication Antitumor activity has been shown in multiple preclinical models including neuroblastoma, osteosarcoma, and small cell lung cancer .
A&R: Anti-Double-Stranded DNA Antibodies Recognize DNA Presented on HLA Class II Molecules of Systemic Lupus Erythematosus Risk Alleles
Time of Update: 2022-02-18
/>, Morinobu, A. , Mimori, T. and Arase, H. (2022), Anti–Double-Stranded DNA Antibodies Recognize DNA Presented on HLA Class II Molecules of Systemic Lupus Erythematosus Risk Alleles. Arthritis Rheumatol, 74: 105-111
develop and commercialize JS006 (anti-TIGIT monoclonal antibody) in the United States and Canada
Time of Update: 2022-01-25
of exercising the license option of JS006 (anti-TIGIT monoclonal antibody independently developed by Junshi Bio) in the United States and Canada
Youhe Pharmaceutical's Phase I clinical study of anti-4-1BB antibody in Australia completes the first patient administration
Time of Update: 2022-01-12
The main purpose is to evaluate the safety, tolerability and anti-tumor activity of YH004 single-agent and combined anti-PD-1 monoclonal antibody in subjects with advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma, and to evaluate YH004’s Pharmacokinetics and immunogenicity .
Tumor-infiltrating lymphocytes and anti-PD-1 antibodies increase the remission rate of a variety of solid tumors
Time of Update: 2022-01-12
>. Iovance's second-generation TIL production process can complete the production of TIL therapy within 22 days, gaining valuable time for the early start of patient treatment .
The first anti-FcRn monoclonal antibody was approved by the FDA for marketing!
Time of Update: 2022-01-11
Text: Picking up shellsOn December 17, Argenx announced that the US FDA approved VYVGART™ (efgartigimod alfa-fcab) for the treatment of adult systemic myasthenia gravis (gMG) with positive anti-acetylcholine receptor (AChR) antibodies .
for the development and production of anti-PD-L1/CD47 bispecific antibodies
Time of Update: 2022-01-09
62em; font-family:"Arial"; color:black; margin:0in; } Shanghai, China and Seoul, South Korea, December 28, 2021/PRNewswire/ - The world's leading open biopharmaceutical technology platform company WuXi Biologics (WuXi Biologics, 2269.
The first domestic phase I clinical study of anti-ST2 antibody completed the first group of subjects enrolled
Time of Update: 2022-01-08
chain layout, announced that its anti-ST2 antibody (R&D code: 9MW1911) Phase I clinical study has completed the first set in China Healthy subjects were included
